PubMed Health⌕ Search

PubMed · 9711418

Progress in immunoassay technology.

Abstract

Immunoassay is now the most widely used analytical technique in laboratory medicine embracing a vast repertoire of analytes and delivered through an increasingly diverse range of devices. This explosion of analytical techniques is complemented by an increasing knowledge base on the antigen antibody reaction that is being used to explore new and improved methodologies. Our knowledge of the molecular chemistry of the antigen antibody reaction coupled with the molecular biology of immunoglobulin expression has led to the development of antibody and antibody-like molecules with enhanced specificity, and reaction kinetics. These developments include novel fusion proteins, antibody mimics and antibodies that recognise antigen antibody complexes. The advances in the chemistry of the analytical systems are matched by the design of delivery vehicles: on the one hand the automated analyser that facilitates the analysis of large numbers of samples and on the other, the encapsulated, miniaturised device that enables an immunoassay to be performed at the point of care.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

C P Price. 1998. Progress in immunoassay technology.. https://doi.org/10.1515/cclm.1998.057

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

ERBB3 overexpression due to miR-205 inactivation confers sensitivity to FGF, metabolic activation, and liability to ERBB3 targeting in glioblastoma.

In glioblastoma (GBM), the most frequent and lethal brain tumor, therapies suppressing recurrently altered signaling pathways failed to extend survival. However, in patient subsets, specific genetic lesions can confer sensitivity to targeted agents. By exploiting an integrated model based on patient-derived stem-like cells, faithfully recapitulating the original GBMs in vitro and in vivo, here, we identify a human GBM subset (∼9% of all GBMs) characterized by ERBB3 overexpression and nuclear accumulation. ERBB3 overexpression is driven by inheritable promoter methylation or post-transcriptional silencing of the oncosuppressor miR-205 and sustains the malignant phenotype. Overexpressed ERBB3 behaves as a specific signaling platform for fibroblast growth factor receptor (FGFR), driving PI3K/AKT/mTOR pathway hyperactivation, and overall metabolic upregulation. As a result, ERBB3 inhibition by specific antibodies is lethal for GBM stem-like cells and xenotransplants. These findings highlight a subset of patients eligible for ERBB3-targeted therapy.

Antibodies↗

Protein affinity maturation in vivo using E. coli mutator cells.

This protocol provides a simple in vivo strategy for introducing random mutations to a target DNA sequences using E. coli mutator cells. The method has been used in our laboratory for affinity maturation of proteins encoded by target DNA sequences. Selection conditions can be modified for antibody fragments with increased production levels. Growth conditions in E. coli mutator cells can be adjusted to introduce a single random point mutation per kilobase of DNA, approximately equivalent to one codon change per scFv fragment.

Antibodies↗

Anti-Ri-associated paraneoplastic opsoclonus-ataxia syndrome in a man with transitional cell carcinoma.

BACKGROUND: There are several case reports describing paraneoplastic syndromes in patients with various forms of bladder carcinoma. Current immunologic analyses have enabled the identification of the antineuronal autoantibodies associated with specific syndromes. METHODS: A patient with a history of bladder carcinoma presented with opsoclonus and myoclonus. RESULTS: Workup confirmed the presence of anti-Ri antibodies in the patient's serum and cerebrospinal fluid. The target Ri antigen was found to be expressed by the tumor. CONCLUSIONS: To the authors' knowledge, there are few reports in the literature describing the long-term clinical follow-up and postmortem evaluation in a patient with this form of paraneoplastic syndrome. More important, the authors believe the current study represents the first time that the presence of anti-Ri antibodies has been noted in a paraneoplastic syndrome associated with transitional cell carcinoma of the bladder.

Antibodies↗